Surgical Robotics Technology
Medtronic announced its Penditure™ Left Atrial Appendage (LAA) Exclusion System has officially received CE Mark approval and will be launched in Europe at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting from October 8-11 in Copenhagen, Denmark. The Penditure device recently surpassed 10,000 clips sold globally.
The Penditure LAA Exclusion System is an innovative, implantable clip that comes pre-loaded on a single-use delivery system for use in left atrial appendage management (LAAM) during concomitant cardiac surgery procedures. The Penditure clip is curved to better match the atrial anatomy1 and designed without fabric for reduced risk of inflammation.2 The Penditure device is the only LAA clip on the market today that can be recaptured, repositioned, and redeployed after deployment during a procedure, putting more control in the hands of surgeons.3
A Commitment to Patients
“The strategic addition of the Penditure Left Atrial Appendage Exclusion System demonstrates our commitment to investing in cardiac surgeons and their growing needs for managing patients with more complex cardiac disease”, said Giuseppe Savoja, Western Europe senior business director for the Cardiac Surgery business, which is part of the Cardiovascular Portfolio at Medtronic. “The Penditure device reinforces our commitment to innovation and provides an important, new, differentiated LAA management option for cardiac surgeons in the care of their patients in Western Europe. We are excited to officially launch the Penditure device in the European market and to feature it at our EACTS booth and Medtronic Training Center as well as during the October 9th Medtronic Lunch Symposium for the first time.”
As the only company serving the entire heart care team of cardiac surgeons and perfusionists, Medtronic offers the most robust Cardiac Surgery portfolio available today. Medtronic is committed to innovating in heart valves, surgical ablation, left atrial appendage management (LAAM), revascularization, perfusion, cannulation technologies, and ECMO therapies to advance treatment options, providing distinct benefits to physicians and clinicians, enabling them to focus on the holistic lifetime management of patients.
“Clinicians expect more from Medtronic and we are uniquely positioned to meet these needs to better serve their patients,” said Pieter Kappetein, Ph.D., M.D., chief medical officer, Cardiac Surgery, Medtronic. “The Penditure LAA Exclusion System brings innovation to the space, with a wide opening at the base offering good visibility, which may assist in proper clip placement. Surgeons can place the Penditure LAA Exclusion System confidently while having the added benefit of recapturability after initial deployment if needed.”
Source: Medtronic
